{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:15:40Z","timestamp":1790874940057,"version":"4.1.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Westpac Research Fellowhip","award":["2021"],"award-info":[{"award-number":["2021"]}]},{"DOI":"10.13039\/501100001047","name":"Ian Potter Foundation","doi-asserted-by":"publisher","award":["31110414"],"award-info":[{"award-number":["31110414"]}],"id":[{"id":"10.13039\/501100001047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001047","name":"Ian Potter Foundation","doi-asserted-by":"publisher","award":["31110414"],"award-info":[{"award-number":["31110414"]}],"id":[{"id":"10.13039\/501100001047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1110341"],"award-info":[{"award-number":["1110341"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A better understanding of the endocannabinoid system and a relaxation in regulatory control of cannabis globally has increased interest in the medicinal use of cannabinoid-based products (CBP). We provide a systematic review of the rationale and current clinical trial evidence for CBP in the treatment of neuropsychiatric and neurodevelopmental disorders in children and adolescents. A systematic search of MEDLINE, Embase, PsycINFO, and the Cochrane Central Register of Trials\u00a0was performed to identify articles published after 1980 about CBP for medical purposes in individuals aged 18\u00a0years or younger with selected neuropsychiatric or neurodevelopmental conditions. Risk of bias and quality of evidence was assessed for each article. Of\u00a04466 articles screened, 18 were eligible for inclusion, addressing eight conditions (anxiety disorders (<jats:italic>n<\/jats:italic>\u2009=\u20091); autism spectrum disorder (<jats:italic>n<\/jats:italic>\u2009=\u20095); foetal alcohol spectrum disorder (<jats:italic>n<\/jats:italic>\u2009=\u20091); fragile X syndrome (<jats:italic>n<\/jats:italic>\u2009=\u20092); intellectual disability (<jats:italic>n<\/jats:italic>\u2009=\u20091); mood disorders (<jats:italic>n<\/jats:italic>\u2009=\u20092); post-traumatic stress disorder (<jats:italic>n<\/jats:italic>\u2009=\u20093); and Tourette syndrome (<jats:italic>n<\/jats:italic>\u2009=\u20093)). Only one randomised controlled trial (RCT) was identified. The remaining seventeen articles included one open-label trial, three uncontrolled before-and-after trials, two case series and 11 case reports, thus the risk of bias was high. Despite growing community and scientific interest, our systematic review identified limited and generally poor-quality evidence for the efficacy of CBP in neuropsychiatric and neurodevelopmental disorders in children and adolescents. Large rigorous RCTs are required to inform clinical care. In the meantime, clinicians must balance patient expectations with the limited evidence available.<\/jats:p>","DOI":"10.1007\/s00787-023-02169-w","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T02:02:28Z","timestamp":1677808948000},"page":"505-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2315-7698","authenticated-orcid":false,"given":"Lauren J.","family":"Rice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1744-812X","authenticated-orcid":false,"given":"Lisa","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6202-1718","authenticated-orcid":false,"given":"Navin","family":"Dadlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7598-8648","authenticated-orcid":false,"given":"Melissa Mei Yin","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6940-5215","authenticated-orcid":false,"given":"Stewart L.","family":"Einfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2810-4496","authenticated-orcid":false,"given":"Daryl","family":"Efron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6282-445X","authenticated-orcid":false,"given":"David R.","family":"Dossetor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6501-5487","authenticated-orcid":false,"given":"Elizabeth J.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"2169_CR1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd1495","volume":"3","author":"VD Marzo","year":"2004","unstructured":"Marzo VD, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771\u2013784","journal-title":"Nat Rev Drug Discov"},{"key":"2169_CR2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejphar.2004.07.033","volume":"500","author":"E Fride","year":"2004","unstructured":"Fride E (2004) The endocannabinoid-CB1 receptor system in pre-and postnatal life. Eur J Pharmacol 500:289\u2013297","journal-title":"Eur J Pharmacol"},{"key":"2169_CR3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev-neuro-062111-150420","volume":"35","author":"I Katona","year":"2012","unstructured":"Katona I, Freund TF (2012) Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci 35:529\u2013558","journal-title":"Annu Rev Neurosci"},{"key":"2169_CR4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nrn4036","volume":"16","author":"B Lutz","year":"2015","unstructured":"Lutz B, Marsicano G, Maldonado R, Hillard CJ (2015) The endocannabinoid system in guarding against fear, anxiety and stress. Nat Rev Neurosci 16:705\u2013718","journal-title":"Nat Rev Neurosci"},{"key":"2169_CR5","volume":"11","author":"MJ Pava","year":"2016","unstructured":"Pava MJ, Makriyannis A, Lovinger DM (2016) Endocannabinoid signaling regulates sleep stability. PLoS ONE 11:e0152473","journal-title":"PLoS ONE"},{"key":"2169_CR6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fnbeh.2011.00057","volume":"5","author":"C Zanettini","year":"2011","unstructured":"Zanettini C, Panlilio LV, Aliczki M, Goldberg SR, Haller J, Yasar S (2011) Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front Behav Neurosci 5:57","journal-title":"Front Behav Neurosci"},{"key":"2169_CR7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","volume":"54","author":"A Howlett","year":"2002","unstructured":"Howlett A, Barth F, Bonner T, Cabral G, Casellas P, Devane W, Felder C, Herkenham M, Mackie K, Martin B (2002) International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161\u2013202","journal-title":"Pharmacol Rev"},{"key":"2169_CR8","first-page":"607","volume":"6","author":"H-C Lu","year":"2021","unstructured":"Lu H-C, Mackie K (2021) Review of the endocannabinoid system. Biol Psychiatry Cogn Neurosci Neuroimaging 6:607\u2013615","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"2169_CR9","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1002\/jcph.1871","volume":"61","author":"JD Brown","year":"2021","unstructured":"Brown JD, Rivera Rivera KJ, Hernandez LYC, Doenges MR, Auchey I, Pham T, Goodin AJ (2021) Natural and synthetic cannabinoids: pharmacology, uses, adverse drug events, and drug interactions. J Clin Pharmacol 61:S37\u2013S52","journal-title":"J Clin Pharmacol"},{"key":"2169_CR10","doi-asserted-by":"crossref","DOI":"10.4324\/9780429427794","volume-title":"Legalizing cannabis: experiences, lessons and scenarios","author":"T Decorte","year":"2020","unstructured":"Decorte T, Lenton S, Wilkins C (2020) Legalizing cannabis: experiences, lessons and scenarios. Routledge"},{"key":"2169_CR11","doi-asserted-by":"crossref","unstructured":"Oldfeld K, Evans S, Braithwaite I, Newton-Howes G (2021) Don\u2019t make a hash of it! A thematic review of the literature relating to outcomes of cannabis regulatory change. Drug Educ Prev Policy","DOI":"10.1080\/09687637.2021.1901855"},{"key":"2169_CR12","unstructured":"(2022) Legality of cannabis. In: Wikipedia"},{"key":"2169_CR13","unstructured":"Australian Government Department of Health (2020) Submission to the Senate Community Affairs References Committee, Senate inquiry into the current barriers to patient access to medicinal cannabis in Australia. In: Canberra"},{"key":"2169_CR14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/dmcn.14087","volume":"61","author":"S Ali","year":"2019","unstructured":"Ali S, Scheffer IE, Sadleir LG (2019) Efficacy of cannabinoids in paediatric epilepsy. Dev Med Child Neurol 61:13\u201318","journal-title":"Dev Med Child Neurol"},{"key":"2169_CR15","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/jnnp-2017-317168","volume":"89","author":"E Stockings","year":"2018","unstructured":"Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S et al (2018) Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry 89:741\u2013753","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2169_CR16","unstructured":"Australian Government Department of Health and Aged Care Therapeutic Goods Administration (2021) Medicinal cannabis special access scheme category B data. In: Commonwealth of Australia"},{"key":"2169_CR17","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1001\/jama.296.16.1981","volume":"296","author":"SL Einfeld","year":"2006","unstructured":"Einfeld SL, Piccinin AM, Mackinnon A, Hofer SM, Taffe J, Gray KM, Bontempo DE, Hoffman LR, Parmenter T, Tonge BJ (2006) Psychopathology in young people with intellectual disability. JAMA 296:1981\u20131989","journal-title":"JAMA"},{"key":"2169_CR18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1365-2788.2003.00464.x","volume":"47","author":"E Emerson","year":"2003","unstructured":"Emerson E (2003) Prevalence of psychiatric disorders in children and adolescents with and without intellectual disability. J Intellect Disabil Res 47:51\u201358","journal-title":"J Intellect Disabil Res"},{"key":"2169_CR19","first-page":"168","volume":"6","author":"RC Kessler","year":"2007","unstructured":"Kessler RC, Angermeyer M, Anthony JC, De Graaf R, Demyttenaere K, Gasquet I, De Girolamo G, Gluzman S, Gureje O, Haro JM (2007) Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization\u2019s World Mental Health Survey Initiative. World Psychiatry 6:168","journal-title":"World Psychiatry"},{"key":"2169_CR20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/13668250.2011.648609","volume":"37","author":"CM Doran","year":"2012","unstructured":"Doran CM, Einfeld SL, Madden RH, Otim M, Horstead SK, Ellis LA, Emerson E (2012) How much does intellectual disability really cost? First estimates for Australia. J Intellect Dev Disabil 37:42\u201349","journal-title":"J Intellect Dev Disabil"},{"key":"2169_CR21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/19315864.2010.524973","volume":"3","author":"SL Einfeld","year":"2010","unstructured":"Einfeld SL, Ellis LA, Doran CM, Emerson E, Horstead SK, Madden RH, Tonge BJ (2010) Behavior problems increase costs of care of children with intellectual disabilities. J Ment Health Res Intell Disabil 3:202\u2013209","journal-title":"J Ment Health Res Intell Disabil"},{"key":"2169_CR22","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/jpc.13615","volume":"53","author":"D Efron","year":"2017","unstructured":"Efron D, Danchin MH, Cranswick NE, Gulenc A, Hearps S, Hiscock H (2017) Medication prescribed by Australian paediatricians: psychotropics predominate. J Paediatr Child Health 53:957\u2013962","journal-title":"J Paediatr Child Health"},{"key":"2169_CR23","volume":"351","author":"R Sheehan","year":"2015","unstructured":"Sheehan R, Hassiotis A, Walters K, Osborn D, Strydom A, Horsfall L (2015) Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ 351:h4326","journal-title":"BMJ"},{"key":"2169_CR24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1089\/cap.2018.0040","volume":"28","author":"JB Edgcomb","year":"2018","unstructured":"Edgcomb JB, Zima B (2018) Medication adherence among children and adolescents with severe mental illness: a systematic review and meta-analysis. J Child Adolesc Psychopharmacol 28:508\u2013520","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2169_CR25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5350\/DAJPN2018310107","volume":"31","author":"MB Usta","year":"2018","unstructured":"Usta MB, Gumus YY, Aral A, Say GN, Karabekiroglu K (2018) Psychotropic medication use in children and adolescents: review of outpatient treatments. Dusunen Adam J Psychiatry Neurol Sci 31:72","journal-title":"Dusunen Adam J Psychiatry Neurol Sci"},{"key":"2169_CR26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.rasd.2012.08.001","volume":"7","author":"D Cohen","year":"2013","unstructured":"Cohen D, Raffin M, Canitano R, Bodeau N, Bonnot O, P\u00e9risse D, Consoli A, Laurent C (2013) Risperidone or aripiprazole in children and adolescents with autism and\/or intellectual disability: a Bayesian meta-analysis of efficacy and secondary effects. Res Autism Spectr Disord 7:167\u2013175","journal-title":"Res Autism Spectr Disord"},{"key":"2169_CR27","doi-asserted-by":"crossref","unstructured":"McKee KA, Hmidan A, Crocker CE, Lam RW, Meyer JH, Crockford D, Tr\u00e9panier A, Aitchison KJ, Tibbo PG (2021) Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: a systematic review and meta-analysis of randomised controlled trials. J Psychiatr Res","DOI":"10.1016\/j.jpsychires.2021.05.044"},{"key":"2169_CR28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1176\/appi.ps.202000189","volume":"72","author":"CN Stanciu","year":"2021","unstructured":"Stanciu CN, Brunette MF, Teja N, Budney AJ (2021) Evidence for use of cannabinoids in mood disorders, anxiety disorders, and PTSD: a systematic review. Psychiatr Serv (Washington, D.C.) 72:429\u2013436","journal-title":"Psychiatr Serv (Washington, D.C.)"},{"key":"2169_CR29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097","journal-title":"PLoS Med"},{"key":"2169_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-02770-6","volume":"11","author":"N Treves","year":"2021","unstructured":"Treves N, Mor N, Allegaert K, Bassalov H, Berkovitch M, Stolar OE, Matok I (2021) Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis. Sci Rep 11:1\u201311","journal-title":"Sci Rep"},{"key":"2169_CR31","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s13311-015-0371-9","volume":"12","author":"B Chakrabarti","year":"2015","unstructured":"Chakrabarti B, Persico A, Battista N, Maccarrone M (2015) Endocannabinoid signaling in autism. Neurotherapeutics 12:837\u2013847","journal-title":"Neurotherapeutics"},{"key":"2169_CR32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/can.2015.0008","volume":"1","author":"D Wei","year":"2016","unstructured":"Wei D, Dinh D, Lee D, Li D, Anguren A, Moreno-Sanz G, Gall CM, Piomelli D (2016) Enhancement of anandamide-mediated endocannabinoid signaling corrects autism-related social impairment. Cannabis Cannabinoid Res 1:81\u201389","journal-title":"Cannabis Cannabinoid Res"},{"key":"2169_CR33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bbr.2013.04.043","volume":"249","author":"DM Kerr","year":"2013","unstructured":"Kerr DM, Downey L, Conboy M, Finn DP, Roche M (2013) Alterations in the endocannabinoid system in the rat valproic acid model of autism. Behav Brain Res 249:124\u2013132","journal-title":"Behav Brain Res"},{"key":"2169_CR34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13229-019-0256-6","volume":"10","author":"A Aran","year":"2019","unstructured":"Aran A, Eylon M, Harel M, Polianski L, Nemirovski A, Tepper S, Schnapp A, Cassuto H, Wattad N, Tam J (2019) Lower circulating endocannabinoid levels in children with autism spectrum disorder. Mol Autism 10:2","journal-title":"Mol Autism"},{"key":"2169_CR35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13229-018-0203-y","volume":"9","author":"DS Karhson","year":"2018","unstructured":"Karhson DS, Krasinska KM, Dallaire JA, Libove RA, Phillips JM, Chien AS, Garner JP, Hardan AY, Parker KJ (2018) Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol Autism 9:18","journal-title":"Mol Autism"},{"key":"2169_CR36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pnpbp.2018.08.030","volume":"89","author":"S Poleg","year":"2019","unstructured":"Poleg S, Golubchik P, Offen D, Weizman A (2019) Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry 89:90\u201396","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2169_CR37","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1007\/s10803-013-1824-9","volume":"43","author":"D Siniscalco","year":"2013","unstructured":"Siniscalco D, Sapone A, Giordano C, Cirillo A, de Magistris L, Rossi F, Fasano A, Bradstreet JJ, Maione S, Antonucci N (2013) Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. J Autism Dev Disord 43:2686\u20132695","journal-title":"J Autism Dev Disord"},{"key":"2169_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-019-2259-4","volume":"19","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Burke SL, Maddux M (2019) Current state of evidence of cannabis utilization for treatment of autism spectrum disorders. BMC Psychiatry 19:1\u201310","journal-title":"BMC Psychiatry"},{"key":"2169_CR39","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3389\/fphar.2018.01521","volume":"9","author":"D Barchel","year":"2019","unstructured":"Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Fuchs DO, Koren G, Berkovitch M (2019) Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Front Pharmacol 9:1521","journal-title":"Front Pharmacol"},{"key":"2169_CR40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13229-021-00420-2","volume":"12","author":"A Aran","year":"2021","unstructured":"Aran A, Harel M, Cassuto H, Polyansky L, Schnapp A, Wattad N, Shmueli D, Golan D, Castellanos FX (2021) Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism 12:6","journal-title":"Mol Autism"},{"key":"2169_CR41","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10803-018-3808-2","volume":"49","author":"A Aran","year":"2019","unstructured":"Aran A, Cassuto H, Lubotzky A, Wattad N, Hazan E (2019) Brief report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems-a retrospective feasibility study. J Autism Dev Disord 49:1284\u20131288","journal-title":"J Autism Dev Disord"},{"key":"2169_CR42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41598-018-37570-y","volume":"9","author":"L Bar-Lev Schleider","year":"2019","unstructured":"Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V (2019) Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep 9:200","journal-title":"Sci Rep"},{"key":"2169_CR43","doi-asserted-by":"crossref","unstructured":"Fleury-Teixeira P, Caixeta FV, da Silva LCR, Brasil-Neto JP, Malcher-Lopes R (2019) Effects of cbd-enriched cannabis sativa extract on autism spectrum disorder symptoms: an observational study of 18 participants undergoing compassionate use. Front Neurol 10 (no pagination)","DOI":"10.3389\/fneur.2019.01145"},{"key":"2169_CR44","first-page":"4","volume":"5","author":"R Kurz","year":"2010","unstructured":"Kurz R, Blaas K (2010) Use of dronabinol (delta-9-THC) in autism: a prospective single-case-study with an early infantile autistic child. Cannabinoids 5:4\u20136","journal-title":"Cannabinoids"},{"key":"2169_CR45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13256-020-02478-7","volume":"14","author":"JA Ponton","year":"2020","unstructured":"Ponton JA, Smyth K, Soumbasis E, Llanos SA, Lewis M, Meerholz WA, Tanguay RL (2020) A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: a case report. J Med Case Rep 14:162\u2013162","journal-title":"J Med Case Rep"},{"key":"2169_CR46","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/jamapediatrics.2013.2698","volume":"167","author":"BH King","year":"2013","unstructured":"King BH, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L, Hollander E, Bregman JD, Anagnostou E, Robinson F (2013) Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial. JAMA Pediatr 167:1045\u20131052","journal-title":"JAMA Pediatr"},{"key":"2169_CR47","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","volume":"12","author":"EM Blessing","year":"2015","unstructured":"Blessing EM, Steenkamp MM, Manzanares J, Marmar CR (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12:825\u2013836","journal-title":"Neurotherapeutics"},{"key":"2169_CR48","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12967-020-02518-2","volume":"18","author":"L Sharpe","year":"2020","unstructured":"Sharpe L, Sinclair J, Kramer A, de Manincor M, Sarris J (2020) Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J Transl Med 18:374\u2013374","journal-title":"J Transl Med"},{"key":"2169_CR49","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/jpc.13902","volume":"54","author":"D Efron","year":"2018","unstructured":"Efron D, Freeman J (2018) Medical cannabis for paediatric developmental\u2013behavioural and psychiatric disorders. J Paediatr Child Health 54:715\u2013717","journal-title":"J Paediatr Child Health"},{"key":"2169_CR50","first-page":"1","volume":"2020","author":"D Efron","year":"2020","unstructured":"Efron D, Freeman J, Cranswick N, Payne J, Mulraney M, Prakash C, Lee K, Taylor K, Williams K (2020) A pilot randomized controlled trial of cannabidiol to reduce severe behavioral problems in children and adolescents with intellectual disability. Br Pharmacol Soc 2020:1\u201311","journal-title":"Br Pharmacol Soc"},{"key":"2169_CR51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nm.3127","volume":"19","author":"A Busquets-Garcia","year":"2013","unstructured":"Busquets-Garcia A, Gomis-Gonz\u00e1lez M, Guegan T, Agust\u00edn-Pav\u00f3n C, Pastor A, Mato S, P\u00e9rez-Samart\u00edn A, Matute C, de la Torre R, Dierssen M, Maldonado R, Ozaita A (2013) Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat Med 19:603\u2013607","journal-title":"Nat Med"},{"key":"2169_CR52","first-page":"1","volume":"3","author":"K-M Jung","year":"2012","unstructured":"Jung K-M, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, Ginger M, Frick A, DiPatrizio NV, Mackie K (2012) Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun 3:1\u201311","journal-title":"Nat Commun"},{"key":"2169_CR53","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/ijms23041935","volume":"23","author":"DD Protic","year":"2022","unstructured":"Protic DD, Aishworiya R, Salcedo-Arellano MJ, Tang SJ, Milisavljevic J, Mitrovic F, Hagerman RJ, Budimirovic DB (2022) Fragile X syndrome: from molecular aspect to clinical treatment. Int J Mol Sci 23:1935","journal-title":"Int J Mol Sci"},{"key":"2169_CR54","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tips.2008.03.001","volume":"29","author":"V Di Marzo","year":"2008","unstructured":"Di Marzo V, Maccarrone M (2008) FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci 29:229\u2013233","journal-title":"Trends Pharmacol Sci"},{"key":"2169_CR55","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","volume":"290","author":"MW Elmes","year":"2015","unstructured":"Elmes MW, Kaczocha M, Berger WT, Leung K, Ralph BP, Wang L, Sweeney JM, Miyauchi JT, Tsirka SE, Ojima I (2015) Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem 290:8711\u20138721","journal-title":"J Biol Chem"},{"key":"2169_CR56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/can.2018.0053","volume":"4","author":"N Tartaglia","year":"2019","unstructured":"Tartaglia N, Bonn-Miller M, Hagerman R (2019) Treatment of fragile X syndrome with cannabidiol: a case series study and brief review of the literature. Cannabis Cannabinoid Res 4:3\u20139","journal-title":"Cannabis Cannabinoid Res"},{"key":"2169_CR57","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s11689-019-9277-x","volume":"11","author":"H Heussler","year":"2019","unstructured":"Heussler H, Cohen J, Silove N, Tich N, Bonn-Miller MO, Du W, O\u2019Neill C, Sebree T (2019) A phase 1\/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. J Neurodev Disord 11:16","journal-title":"J Neurodev Disord"},{"key":"2169_CR58","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00213-001-0946-5","volume":"159","author":"M Martin","year":"2002","unstructured":"Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002) Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159:379\u2013387","journal-title":"Psychopharmacology"},{"key":"2169_CR59","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1590\/S1516-44462009000200012","volume":"31","author":"FA Moreira","year":"2009","unstructured":"Moreira FA, Crippa JAS (2009) The psychiatric side-effects of rimonabant. Braz J Psychiatry 31:145\u2013153","journal-title":"Braz J Psychiatry"},{"key":"2169_CR60","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bbr.2016.01.033","volume":"303","author":"A Sartim","year":"2016","unstructured":"Sartim A, Guimar\u00e3es F, Joca S (2016) Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex\u2014possible involvement of 5-HT1A and CB1 receptors. Behav Brain Res 303:218\u2013227","journal-title":"Behav Brain Res"},{"key":"2169_CR61","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","volume":"159","author":"T Zanelati","year":"2010","unstructured":"Zanelati T, Biojone C, Moreira F, Guimar\u00e3es F, Joca SR (2010) Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 159:122\u2013128","journal-title":"Br J Pharmacol"},{"key":"2169_CR62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0004867420979353","volume":"55","author":"GS Malhi","year":"2021","unstructured":"Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, Hopwood M, Lyndon B, Mulder R, Porter R (2021) The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 55:7\u2013117","journal-title":"Aust N Z J Psychiatry"},{"key":"2169_CR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7517-2-18","volume":"2","author":"W Swift","year":"2005","unstructured":"Swift W, Gates P, Dillon P (2005) Survey of Australians using cannabis for medical purposes. Harm Reduct J 2:1\u201310","journal-title":"Harm Reduct J"},{"key":"2169_CR64","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/can.2018.0006","volume":"3","author":"J Corroon","year":"2018","unstructured":"Corroon J, Phillips JA (2018) A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res 3:152\u2013161","journal-title":"Cannabis Cannabinoid Res"},{"key":"2169_CR65","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuro.2019.08.002","volume":"74","author":"S Bonaccorso","year":"2019","unstructured":"Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F (2019) Cannabidiol (CBD) use in psychiatric disorders: a systematic review. Neurotoxicology 74:282\u2013298","journal-title":"Neurotoxicology"},{"key":"2169_CR66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/0706743719895195","volume":"65","author":"JV Pinto","year":"2020","unstructured":"Pinto JV, Saraf G, Frysch C, Vigo D, Keramatian K, Chakrabarty T, Lam RW, Kauer-Sant\u2019Anna M, Yatham LN (2020) Cannabidiol as a treatment for mood disorders: a systematic review. Can J Psychiatry 65:213\u2013227","journal-title":"Can J Psychiatry"},{"key":"2169_CR67","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/0269881108096521","volume":"24","author":"AW Zuardi","year":"2010","unstructured":"Zuardi AW, Crippa J, Dursun S, Morais S, Vilela J, Sanches R, Hallak J (2010) Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol 24:135\u2013137","journal-title":"J Psychopharmacol"},{"key":"2169_CR68","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1176\/appi.ps.202000189","volume":"72","author":"CN Stanciu","year":"2021","unstructured":"Stanciu CN, Brunette MF, Teja N, Budney AJ (2021) Evidence for use of cannabinoids in mood disorders, anxiety disorders, and PTSD: a systematic review. Psychiatr Serv 72:429\u2013436","journal-title":"Psychiatr Serv"},{"key":"2169_CR69","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/(SICI)1522-7162(1996)4:2<77::AID-DEPR7>3.0.CO;2-C","volume":"4","author":"AJ Gruber","year":"1996","unstructured":"Gruber AJ, Pope HG Jr, Brown ME (1996) Do patients use marijuana as an antidepressant? Depression 4:77\u201380","journal-title":"Depression"},{"key":"2169_CR70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40211-020-00334-0","volume":"35","author":"C Laczkovics","year":"2021","unstructured":"Laczkovics C, Kothgassner OD, Felnhofer A, Klier CM (2021) Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression. Neuropsychiatrie 35:31\u201334","journal-title":"Neuropsychiatrie"},{"key":"2169_CR71","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40263-019-00669-5","volume":"33","author":"RG Dos Santos","year":"2019","unstructured":"Dos Santos RG, de Lima OF, Martin-Santos R, Zuardi AW, Hallak JEC, Crippa JAS (2019) Modulation of the endocannabinoid and oxytocinergic systems as a potential treatment approach for social anxiety disorder. CNS Drugs 33:1031\u20131038","journal-title":"CNS Drugs"},{"key":"2169_CR72","first-page":"1575","volume":"10","author":"MS Garc\u00eda-Guti\u00e9rrez","year":"2020","unstructured":"Garc\u00eda-Guti\u00e9rrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J (2020) Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules (Basel, Switzerland) 10:1575","journal-title":"Biomolecules (Basel, Switzerland)"},{"key":"2169_CR73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11920-019-1026-z","volume":"21","author":"EP Papagianni","year":"2019","unstructured":"Papagianni EP, Stevenson CW (2019) Cannabinoid regulation of fear and anxiety: an update. Curr Psychiatry Rep 21:1\u201310","journal-title":"Curr Psychiatry Rep"},{"key":"2169_CR74","unstructured":"Maldonado R, Caba\u00f1ero D, Mart\u00edn-Garc\u00eda E (2022) The endocannabinoid system in modulating fear, anxiety, and stress. Dialog Clin Neurosci"},{"key":"2169_CR75","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/s41386-019-0416-6","volume":"44","author":"MZ Hammoud","year":"2019","unstructured":"Hammoud MZ, Peters C, Hatfield JR, Gorka SM, Phan KL, Milad MR, Rabinak CA (2019) Influence of \u03949-tetrahydrocannabinol on long-term neural correlates of threat extinction memory retention in humans. Neuropsychopharmacology 44:1769\u20131777","journal-title":"Neuropsychopharmacology"},{"issue":"1062\u20131076","key":"2169_CR76","volume":"105","author":"DJ Marcus","year":"2020","unstructured":"Marcus DJ, Bedse G, Gaulden AD, Ryan JD, Kondev V, Winters ND, Rosas-Vidal LE, Altemus M, Mackie K, Lee FS (2020) Endocannabinoid signaling collapse mediates stress-induced amygdalo-cortical strengthening. Neuron 105(1062\u20131076):e1066","journal-title":"Neuron"},{"key":"2169_CR77","doi-asserted-by":"crossref","unstructured":"Bahji A, Meyyappan AC, Hawken ER (2020) Efficacy and acceptability of cannabinoids for anxiety disorders in adults: a systematic review and meta-analysis. J Psychiatr Res","DOI":"10.1016\/j.jpsychires.2020.07.030"},{"key":"2169_CR78","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/JCP.0000000000001152","volume":"40","author":"CM Klier","year":"2020","unstructured":"Klier CM, de Gier C, Felnhofer A, Laczkovics C, Amminger PG (2020) A case report of cannabidiol treatment of a Crohn\u2019s disease patient with anxiety disorder. J Clin Psychopharmacol 40:90\u201392","journal-title":"J Clin Psychopharmacol"},{"key":"2169_CR79","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.neuroimage.2005.03.047","volume":"29","author":"LM Williams","year":"2006","unstructured":"Williams LM, Kemp AH, Felmingham K, Barton M, Olivieri G, Peduto A, Gordon E, Bryant RA (2006) Trauma modulates amygdala and medial prefrontal responses to consciously attended fear. Neuroimage 29:347\u2013357","journal-title":"Neuroimage"},{"key":"2169_CR80","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.neubiorev.2012.06.003","volume":"36","author":"R Patel","year":"2012","unstructured":"Patel R, Spreng RN, Shin LM, Girard TA (2012) Neurocircuitry models of posttraumatic stress disorder and beyond: a meta-analysis of functional neuroimaging studies. Neurosci Biobehav Rev 36:2130\u20132142","journal-title":"Neurosci Biobehav Rev"},{"key":"2169_CR81","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1176\/appi.ajp.2007.07030504","volume":"164","author":"A Etkin","year":"2007","unstructured":"Etkin A, Wager TD (2007) Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 164:1476\u20131488","journal-title":"Am J Psychiatry"},{"key":"2169_CR82","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1016\/j.psyneuen.2013.08.004","volume":"38","author":"MN Hill","year":"2013","unstructured":"Hill MN, Bierer LM, Makotkine I, Golier JA, Galea S, McEwen BS, Hillard CJ, Yehuda R (2013) Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology 38:2952\u20132961","journal-title":"Psychoneuroendocrinology"},{"key":"2169_CR83","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/mp.2013.61","volume":"18","author":"A Neumeister","year":"2013","unstructured":"Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng M-Q, Gujarro-Anton A, Potenza MN, Bailey CR, Lin S, Najafzadeh S (2013) Elevated brain cannabinoid CB 1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 18:1034\u20131040","journal-title":"Mol Psychiatry"},{"key":"2169_CR84","doi-asserted-by":"crossref","first-page":"9953","DOI":"10.1523\/JNEUROSCI.2134-04.2004","volume":"24","author":"SC Azad","year":"2004","unstructured":"Azad SC, Monory K, Marsicano G, Cravatt BF, Lutz B, Zieglg\u00e4nsberger W, Rammes G (2004) Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J Neurosci 24:9953\u20139961","journal-title":"J Neurosci"},{"key":"2169_CR85","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.nlm.2013.09.009","volume":"113","author":"CA Rabinak","year":"2014","unstructured":"Rabinak CA, Angstadt M, Lyons M, Mori S, Milad MR, Liberzon I, Phan KL (2014) Cannabinoid modulation of prefrontal\u2013limbic activation during fear extinction learning and recall in humans. Neurobiol Learn Mem 113:125\u2013134","journal-title":"Neurobiol Learn Mem"},{"key":"2169_CR86","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/15504263.2019.1652380","volume":"16","author":"C Hindocha","year":"2020","unstructured":"Hindocha C, Cousijn J, Rall M, Bloomfield MAP (2020) The effectiveness of cannabinoids in the treatment of posttraumatic stress disorder (PTSD): a systematic review. J Dual Diagn 16:120\u2013139","journal-title":"J Dual Diagn"},{"key":"2169_CR87","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","volume":"51","author":"R Jetly","year":"2015","unstructured":"Jetly R, Heber A, Fraser G, Boisvert D (2015) The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 51:585\u2013588","journal-title":"Psychoneuroendocrinology"},{"key":"2169_CR88","doi-asserted-by":"crossref","unstructured":"Bolsoni LM, da Silva TDA, Quintana SM, de Castro M, Crippa JA, Zuardi AW (2019) Changes in cortisol awakening response before and after development of posttraumatic stress disorder, which cannot be avoided with use of cannabidiol: a case report. Permanente J 23","DOI":"10.7812\/TPP\/18.300"},{"key":"2169_CR89","first-page":"40","volume":"25","author":"R Lorenz","year":"2004","unstructured":"Lorenz R (2004) On the application of cannabis in paediatrics and epileptology. Neuro Endocrinol Lett 25:40\u201344","journal-title":"Neuro Endocrinol Lett"},{"key":"2169_CR90","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7812\/TPP\/16-005","volume":"20","author":"S Shannon","year":"2016","unstructured":"Shannon S, Opila-Lehman J (2016) Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. Permanente J 20:16\u2013005","journal-title":"Permanente J"},{"key":"2169_CR91","doi-asserted-by":"crossref","unstructured":"Curtis A, Clarke CE, Rickards HE (2009) Cannabinoids for Tourette's Syndrome. Cochrane Database Syst Rev","DOI":"10.1002\/14651858.CD006565.pub2"},{"key":"2169_CR92","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s13311-015-0376-4","volume":"12","author":"BS Koppel","year":"2015","unstructured":"Koppel BS (2015) Cannabis in the treatment of dystonia, dyskinesias, and tics. Neurotherapeutics 12:788\u2013792","journal-title":"Neurotherapeutics"},{"key":"2169_CR93","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4088\/JCP.v64n0417","volume":"64","author":"KR M\u00fcller-Vahl","year":"2003","unstructured":"M\u00fcller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM (2003) Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 64:459\u2013465","journal-title":"J Clin Psychiatry"},{"key":"2169_CR94","doi-asserted-by":"crossref","first-page":"16097","DOI":"10.1038\/nrdp.2016.97","volume":"3","author":"MM Robertson","year":"2017","unstructured":"Robertson MM, Eapen V, Singer HS, Martino D, Scharf JM, Paschou P, Roessner V, Woods DW, Hariz M, Mathews CA, \u010crn\u010dec R, Leckman JF (2017) Gilles de la Tourette syndrome. Nat Rev Dis Primers 3:16097","journal-title":"Nat Rev Dis Primers"},{"key":"2169_CR95","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41386-020-0671-6","volume":"45","author":"KR M\u00fcller-Vahl","year":"2020","unstructured":"M\u00fcller-Vahl KR, Bindila L, Lutz B, Musshoff F, Skripuletz T, Baumgaertel C, S\u00fchs K-W (2020) Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome. Neuropsychopharmacology 45:1323\u20131329","journal-title":"Neuropsychopharmacology"},{"key":"2169_CR96","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.neuropsych.16110310","volume":"29","author":"E Abi-Jaoude","year":"2017","unstructured":"Abi-Jaoude E, Chen L, Cheung P, Bhikram T, Sandor P (2017) Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette syndrome. J Neuropsychiatry Clin Neurosci 29:391\u2013400","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2169_CR97","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/1039856216663737","volume":"24","author":"D Trainor","year":"2016","unstructured":"Trainor D, Evans L, Bird R (2016) Severe motor and vocal tics controlled with Sativex\u00ae. Australas Psychiatry 24:541\u2013544","journal-title":"Australas Psychiatry"},{"key":"2169_CR98","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/brainsci7050047","volume":"7","author":"AS Kanaan","year":"2017","unstructured":"Kanaan AS, Ewgeni J, M\u00fcller-Vahl KR (2017) Significant tic reduction in an otherwise treatment-resistant patient with Gilles de la Tourette syndrome following treatment with nabiximols. Brain Sci 7:47","journal-title":"Brain Sci"},{"key":"2169_CR99","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1212\/WNL.0000000000000363","volume":"82","author":"BS Koppel","year":"2014","unstructured":"Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D (2014) Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82:1556\u20131563","journal-title":"Neurology"},{"key":"2169_CR100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.9758\/cpn.2017.15.4.301","volume":"15","author":"K Lim","year":"2017","unstructured":"Lim K, See YM, Lee J (2017) A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders. Clin Psychopharmacol Neurosci 15:301\u2013312","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"2169_CR101","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12906-019-2803-2","volume":"20","author":"N Montero-Oleas","year":"2020","unstructured":"Montero-Oleas N, Arevalo-Rodriguez I, Nu\u00f1ez-Gonz\u00e1lez S, Viteri-Garc\u00eda A, Simancas-Racines D (2020) Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews. BMC Complement Med Ther 20:12","journal-title":"BMC Complement Med Ther"},{"key":"2169_CR102","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-2002-25028","volume":"35","author":"KR M\u00fcller-Vahl","year":"2002","unstructured":"M\u00fcller-Vahl KR, Schneider U, Koblenz A, J\u00f6bges M, Kolbe H, Daldrup T, Emrich HM (2002) Treatment of Tourette\u2019s syndrome with \u03949-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35:57\u201361","journal-title":"Pharmacopsychiatry"},{"key":"2169_CR103","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/JCP.0b013e3181d236ec","volume":"30","author":"A Hasan","year":"2010","unstructured":"Hasan A, Rothenberger A, Munchau A, Wobrock T, Falkai P, Roessner V (2010) Oral DELTA9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report. J Clin Psychopharmacol 30:190\u2013192","journal-title":"J Clin Psychopharmacol"},{"key":"2169_CR104","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3390\/ijms18081739","volume":"18","author":"E Jakubovski","year":"2017","unstructured":"Jakubovski E, Muller-Vahl K (2017) Speechlessness in Gilles de la Tourette Syndrome: Cannabis-based medicines improve severe vocal blocking tics in two patients. Int J Mol Sci 18:1739","journal-title":"Int J Mol Sci"},{"key":"2169_CR105","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1600-0447.1998.tb10127.x","volume":"98","author":"KR M\u00fcller-Vahl","year":"1998","unstructured":"M\u00fcller-Vahl KR, Kolbe H, Schneider U, Emrich HM (1998) Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand 98:502\u2013506","journal-title":"Acta Psychiatr Scand"},{"key":"2169_CR106","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1503\/cmaj.141593","volume":"188","author":"JL Cook","year":"2016","unstructured":"Cook JL, Green CR, Lilley CM, Anderson SM, Baldwin ME, Chudley AE, Conry JL, LeBlanc N, Loock CA, Lutke J, Mallon BF, McFarlane AA, Temple VK, Rosales T, Network ftCFASDR, (2016) Fetal alcohol spectrum disorder: a guideline for diagnosis across the lifespan. CMAJ Can Med Assoc J 188:191\u2013197","journal-title":"CMAJ Can Med Assoc J"},{"key":"2169_CR107","unstructured":"Bower C, Elliott E, on behalf of the Steering Group (2020) Report to the Australian Government Department of Health: 'Australian guide to the diagnosis of Fetal Alcohol Spectrum Disorder (FASD)'"},{"key":"2169_CR108","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3390\/brainsci5040456","volume":"5","author":"BS Basavarajappa","year":"2015","unstructured":"Basavarajappa BS (2015) Fetal alcohol spectrum disorder: potential role of endocannabinoids signaling. Brain Sci 5:456\u2013493","journal-title":"Brain Sci"},{"key":"2169_CR109","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3390\/brainsci3031153","volume":"3","author":"CE Creeley","year":"2013","unstructured":"Creeley CE, Olney JW (2013) Drug-induced apoptosis: mechanism by which alcohol and many other drugs can disrupt brain development. Brain Sci 3:1153\u20131181","journal-title":"Brain Sci"},{"key":"2169_CR110","first-page":"e59","volume":"22","author":"J Ozsarfati","year":"2015","unstructured":"Ozsarfati J, Koren G (2015) Medications used in the treatment of disruptive behavior in children with FASD\u2014a guide. J Popul Ther Clin Pharmacol 22:e59-67","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"2169_CR111","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Baos A, Puig-Reyne X, Garc\u00eda-Algar \u00d3OV (2021) Cannabidiol attenuates cognitive deficits and neuroinflammation induced by early alcohol exposure in a mice model. Biomed Pharmacother 11","DOI":"10.1101\/2021.03.16.435465"},{"key":"2169_CR112","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/can.2019.0056","volume":"6","author":"G Koren","year":"2021","unstructured":"Koren G, Cohen R, Sachs O (2021) Use of Cannabis in fetal alcohol spectrum disorder. Cannabis Cannabinoid Res 6:74\u201376","journal-title":"Cannabis Cannabinoid Res"},{"key":"2169_CR113","doi-asserted-by":"crossref","unstructured":"Simonian JS, Varanasi S, Diaz-Fong JP, Richards GJ, Nguyen AV, Hoffman J (2020) A critical narrative review of medical cannabis in pediatrics beyond epilepsy, part II: neurodevelopmental, movement, and pain disorders. Pediatr Med 3","DOI":"10.21037\/pm-20-69"},{"key":"2169_CR114","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00406-019-00984-4","volume":"269","author":"E Hoch","year":"2019","unstructured":"Hoch E, Niemann D, von Keller R, Schneider M, Friemel CM, Preuss UW, Hasan A, Pogarell O (2019) How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. Eur Arch Psychiatry Clin Neurosci 269:87\u2013105","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2169_CR115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12888-019-2409-8","volume":"20","author":"J Sarris","year":"2020","unstructured":"Sarris J, Sinclair J, Karamacoska D, Davidson M, Firth J (2020) Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry 20:24\u201324","journal-title":"BMC Psychiatry"},{"key":"2169_CR116","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","volume":"27","author":"RE Cooper","year":"2017","unstructured":"Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P (2017) Cannabinoids in attention-deficit\/hyperactivity disorder: a randomised-controlled trial. Eur Neuropsychopharmacol 27:795\u2013808","journal-title":"Eur Neuropsychopharmacol"},{"key":"2169_CR117","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jamapsychiatry.2019.0970","volume":"76","author":"A Minichino","year":"2019","unstructured":"Minichino A, Senior M, Brondino N, Zhang SH, Godlewska BR, Burnet PW, Cipriani A, Lennox BR (2019) Measuring disturbance of the endocannabinoid system in psychosis: a systematic review and meta-analysis. JAMA Psychiat 76:914\u2013923","journal-title":"JAMA Psychiat"},{"key":"2169_CR118","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/08897077.2021.1876200","volume":"42","author":"SK Kiburi","year":"2021","unstructured":"Kiburi SK, Molebatsi K, Ntlantsana V, Lynskey MT (2021) Cannabis use in adolescence and risk of psychosis: are there factors that moderate this relationship? A systematic review and meta-analysis. Substance Abuse 42:527\u2013542","journal-title":"Substance Abuse"},{"key":"2169_CR119","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12888-021-03395-9","volume":"21","author":"J\u00d8 Rasmussen","year":"2021","unstructured":"Rasmussen J\u00d8, Jennum P, Linnet K, Glenthaj BY, Baandrup L (2021) Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial. BMC Psychiatry 21:404\u2013404","journal-title":"BMC Psychiatry"},{"key":"2169_CR120","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/brainsci10090572","volume":"10","author":"L Fusar-Poli","year":"2020","unstructured":"Fusar-Poli L, Cavone V, Tinacci S, Concas I, Petralia A, Signorelli MS, D\u00edaz-Caneja CM, Aguglia E (2020) Cannabinoids for people with ASD: a systematic review of published and ongoing studies. Brain Sci 10:572","journal-title":"Brain Sci"},{"key":"2169_CR121","doi-asserted-by":"crossref","first-page":"129","DOI":"10.14740\/jocmr4090","volume":"12","author":"C Larsen","year":"2020","unstructured":"Larsen C, Shahinas J (2020) Dosage, efficacy and safety of cannabidiol administration in adults: a systematic review of human trials. J Clin Med Res 12:129","journal-title":"J Clin Med Res"},{"key":"2169_CR122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42238-019-0012-y","volume":"2","author":"R Khan","year":"2020","unstructured":"Khan R, Naveed S, Mian N, Fida A, Raafey MA, Aedma KK (2020) The therapeutic role of Cannabidiol in mental health: a systematic review. J Cannabis Res 2:1\u201321","journal-title":"J Cannabis Res"},{"key":"2169_CR123","doi-asserted-by":"crossref","unstructured":"Wong SS, Wilens TE (2017) Medical cannabinoids in children and adolescents: a systematic review. Pediatrics 140","DOI":"10.1542\/peds.2017-1818"},{"key":"2169_CR124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-019-2409-8","volume":"20","author":"J Sarris","year":"2020","unstructured":"Sarris J, Sinclair J, Karamacoska D, Davidson M, Firth J (2020) Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry 20:1\u201314","journal-title":"BMC Psychiatry"},{"key":"2169_CR125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1073\/pnas.1920325116","volume":"117","author":"H Shen","year":"2020","unstructured":"Shen H (2020) News feature: Cannabis and the adolescent brain. Proc Natl Acad Sci 117:7\u201311","journal-title":"Proc Natl Acad Sci"},{"key":"2169_CR126","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3389\/fpsyg.2020.00859","volume":"11","author":"G Blest-Hopley","year":"2020","unstructured":"Blest-Hopley G, Colizzi M, Giampietro V, Bhattacharyya S (2020) Is the adolescent brain at greater vulnerability to the effects of cannabis? A narrative review of the evidence. Front Psychol 11:859","journal-title":"Front Psychol"},{"key":"2169_CR127","doi-asserted-by":"crossref","unstructured":"Ellingson JM, Hinckley JD, Ross JM, Schacht JP, Bidwell L, Bryan AD, Hopfer CJ, Riggs P, Hutchison KE (2021) The neurocognitive effects of Cannabis across the lifespan. Curr Behav Neurosci Rep 1\u201310","DOI":"10.1007\/s40473-021-00244-7"},{"key":"2169_CR128","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamapsychiatry.2018.4500","volume":"76","author":"G Gobbi","year":"2019","unstructured":"Gobbi G, Atkin T, Zytynski T, Wang S, Askari S, Boruff J, Ware M, Marmorstein N, Cipriani A, Dendukuri N (2019) Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis. JAMA Psychiatr 76:426\u2013434","journal-title":"JAMA Psychiatr"},{"key":"2169_CR129","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1017\/S0033291713001438","volume":"44","author":"S Lev-Ran","year":"2014","unstructured":"Lev-Ran S, Roerecke M, Le Foll B, George T, McKenzie K, Rehm J (2014) The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med 44:797\u2013810","journal-title":"Psychol Med"},{"key":"2169_CR130","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2215-0366(20)30074-2","volume":"7","author":"G Hindley","year":"2020","unstructured":"Hindley G, Beck K, Borgan F, Ginestet CE, McCutcheon R, Kleinloog D, Ganesh S, Radhakrishnan R, D\u2019Souza DC, Howes OD (2020) Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry 7:344\u2013353","journal-title":"Lancet Psychiatry"},{"key":"2169_CR131","doi-asserted-by":"crossref","unstructured":"Al-Soleiti M, Balaj K, Thom RP, McDougle CJ, Keary CJ (2021) Brief report: suspected cannabis-induced mania and psychosis in young adult males with autism spectrum disorder. J Autism Dev Disord 1\u20138","DOI":"10.1007\/s10803-021-05254-8"},{"key":"2169_CR132","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3389\/fgene.2021.686666","volume":"12","author":"N Robinson","year":"2021","unstructured":"Robinson N, Bergen SE (2021) Environmental risk factors for schizophrenia and bipolar disorder and their relationship to genetic risk: current knowledge and future directions. Front Genet 12:999","journal-title":"Front Genet"},{"key":"2169_CR133","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/17425255.2020.1754793","volume":"16","author":"RG Dos Santos","year":"2020","unstructured":"Dos Santos RG, Guimar\u00e3es FS, Crippa JAS, Hallak JE, Rossi GN, Rocha JM, Zuardi AW (2020) Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. Expert Opin Drug Metab Toxicol 16:517\u2013526","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2169_CR134","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/jcm9040919","volume":"9","author":"JD Brown","year":"2020","unstructured":"Brown JD (2020) Potential adverse drug events with tetrahydrocannabinol (THC) due to drug\u2013drug interactions. J Clin Med 9:919","journal-title":"J Clin Med"},{"key":"2169_CR135","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/jcm8070989","volume":"8","author":"JD Brown","year":"2019","unstructured":"Brown JD, Winterstein AG (2019) Potential adverse drug events and drug\u2013drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med 8:989","journal-title":"J Clin Med"}],"container-title":["European Child &amp; Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-023-02169-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00787-023-02169-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-023-02169-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T07:06:45Z","timestamp":1708326405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00787-023-02169-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":135,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2169"],"URL":"https:\/\/doi.org\/10.1007\/s00787-023-02169-w","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"assertion":[{"value":"27 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}